ArticleJGH open : an open access journal of gastroenterology and hepatology2020

Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.

Tetsu Tomonari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.